diabetic retinopathy

diabetic retinopathy
Name	Diabetic retinopathy
Caption	Fundoscopic appearance of proliferative diabetic retinopathy
Specialty	Ophthalmology, Endocrinology
Symptoms	Visual impairment, floaters, blurred vision
Complications	Vision loss, vitreous hemorrhage, retinal detachment
Onset	Variable
Causes	Chronic hyperglycemia, diabetes mellitus
Risks	Duration of diabetes, hypertension, dyslipidemia
Treatment	Laser photocoagulation, anti-VEGF therapy, vitrectomy
Frequency	Common among people with diabetes

diabetic retinopathy is a microvascular complication of Diabetes mellitus characterized by damage to the retinal vasculature leading to vision impairment. It is a leading cause of preventable blindness worldwide and is managed by coordinated care among World Health Organization, American Diabetes Association, National Health Service (England), and specialist centers. Clinical practice integrates guidelines from organizations such as American Academy of Ophthalmology, International Council of Ophthalmology, and public health programs in countries like United States, United Kingdom, India, and Australia.

Signs and symptoms

Symptoms range from asymptomatic retinal changes to acute visual loss associated with complications involving the macula or vitreous. Early findings include microaneurysms, dot-blot hemorrhages, and hard exudates detectable on retinal examination performed by clinicians in settings such as Moorfields Eye Hospital, Bascom Palmer Eye Institute, Wills Eye Hospital, and community screening programs organized by NHS England Screening Program. Patients may report floaters, photopsia, or progressive blurring of central vision leading to presentation at tertiary centers like Johns Hopkins Hospital or Massachusetts General Hospital. Advanced stages present with neovascularization, tractional retinal detachment, or vitreous hemorrhage prompting referral to retinal surgeons at institutions such as Moorfields, Bascom Palmer, or university hospitals affiliated with Harvard University and University of Oxford.

Pathophysiology

Chronic hyperglycemia from Type 1 diabetes mellitus or Type 2 diabetes mellitus triggers biochemical and cellular changes in retinal capillaries described in research from groups at Joslin Diabetes Center, Karolinska Institute, and Imperial College London. Mechanisms include pericyte loss, basement membrane thickening, endothelial dysfunction, and breakdown of the blood–retinal barrier mediated by pathways investigated by scientists at National Institutes of Health, European Molecular Biology Laboratory, and Max Planck Society. Vascular endothelial growth factor (VEGF) upregulation, inflammatory cytokines, and oxidative stress contribute to neovascularization and macular edema; these processes have been targets in trials run by institutions such as Mayo Clinic, Cleveland Clinic, Stanford University School of Medicine, and pharmaceutical collaborations with Novartis, Regeneron Pharmaceuticals, and Roche. Animal models and molecular studies from Salk Institute and Cold Spring Harbor Laboratory have elucidated angiogenic signaling and leukostasis underlying disease progression.

Classification and staging

Clinical classification frameworks adopted by the American Academy of Ophthalmology and international groups categorize disease into nonproliferative and proliferative stages with subdivisions for severity. The Early Treatment Diabetic Retinopathy Study (ETDRS), coordinated by investigators at University of Wisconsin and National Eye Institute, established grading scales and thresholds for clinically significant macular edema used in trials at institutions including University of California, San Francisco and Johns Hopkins. Ophthalmic societies in Canada, Germany, France, and Japan have adapted these systems for screening and management algorithms used in clinics at Toronto General Hospital, Charité – Universitätsmedizin Berlin, Hôpitaux de Paris, and Tokyo Medical University.

Diagnosis and screening

Diagnosis relies on dilated fundus examination, color fundus photography, optical coherence tomography (OCT), and fluorescein angiography performed in clinics such as Bascom Palmer and imaging centers affiliated with University College London Hospitals. Screening programs implemented by national services including NHS Diabetic Eye Screening Programme and public health initiatives in India and Brazil utilize teleophthalmology, fundus cameras from manufacturers collaborating with King's College London and All India Institute of Medical Sciences, and automated grading supported by research at Massachusetts Institute of Technology and Carnegie Mellon University. International guidelines from bodies like World Health Organization and International Diabetes Federation recommend screening intervals based on duration of diabetes and control, with referral thresholds aligned to ETDRS and other consensus statements from American Diabetes Association panels.

Treatment and management

Management combines systemic metabolic control recommended by American Diabetes Association and local ocular therapies. Laser photocoagulation techniques pioneered by research at University of Minnesota and clinical adoption at centers such as Moorfields remain standard for proliferative disease, while intravitreal anti-VEGF agents developed by Regeneron, Novartis, and Roche are first-line for diabetic macular edema in trials led by teams at National Eye Institute and University of Melbourne. Vitrectomy for nonclearing vitreous hemorrhage or tractional retinal detachment is performed by vitreoretinal surgeons trained at Bascom Palmer, Wills Eye, and academic programs at UCSF and Stanford. Multidisciplinary care models involve endocrinology clinics at centers like Mayo Clinic, primary care networks in Sweden and Netherlands, and patient education initiatives from organizations such as American Association of Clinical Endocrinology.

Epidemiology and risk factors

Global prevalence estimates are reported by the World Health Organization, International Diabetes Federation, and epidemiologic studies conducted by groups at Harvard T.H. Chan School of Public Health, London School of Hygiene & Tropical Medicine, and Public Health England. Risk increases with diabetes duration and inadequate glycemic control documented in cohort studies from Framingham Heart Study, UK Prospective Diabetes Study, and Diabetes Control and Complications Trial investigators. Hypertension, dyslipidemia, pregnancy, smoking, and renal disease heighten risk; these associations have been examined in multinational cohorts coordinated by European Society of Cardiology, American Heart Association, and regional registries in China, Russia, South Africa, and Mexico.

Prevention and prognosis

Primary prevention focuses on glycemic and blood pressure control following evidence from trials conducted by DCCT Research Group, UKPDS Study Group, and guideline panels at American Diabetes Association and European Association for the Study of Diabetes. Screening programs and early treatment improve prognosis, with long-term visual outcomes studied in populations followed by institutions such as Johns Hopkins, Moorfields, and Karolinska University Hospital. Public health strategies from agencies including Centers for Disease Control and Prevention, World Health Organization, and national ministries of health aim to reduce blindness through integrated diabetes care, eye screening, and access to therapies in both high-income and low- and middle-income countries. Category:Eye diseases